On the other hand, studies with KrasLA1 mice, which develop lung adenocarcinoma through somatic activation of a KRAS allele carrying an activating mutation in codon 12 suggested that the presence of KRAS mutations was not sufficient to confer resistance to EGFR inhibition [24]. This evidence concerns the gene EGFR and lung adenocarcinoma.